NCT05098990 is a Phase 4 clinical trial of Jinfukang oral liquid in Non Small Cell Lung Cancer, sponsored by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd..

Who is sponsoring NCT05098990?

NCT05098990 is sponsored by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05098990?

Interventions in NCT05098990: Jinfukang oral liquid, Platinum-based doublet chemotherapy.

What condition does NCT05098990 study?

NCT05098990 studies Non Small Cell Lung Cancer.

Is NCT05098990 still recruiting?

NCT05098990 is currently status unknown. Last updated 29 October 2021.

Last reviewed 2021-10-29 · How we verify

NCT05098990

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

Status unknown Phase 4 Last updated 29 October 2021

What this trial tests

Phase 4 trial testing Jinfukang oral liquid in Non Small Cell Lung Cancer in 328 participants. Status unknown.

Timeline

25 October 2021

Primary endpoint
15 June 2024

15 August 2024

Quick facts

Lead sponsor	China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	328
Start date	25 October 2021
Primary completion	15 June 2024
Estimated completion	15 August 2024

Drugs / interventions tested

Jinfukang oral liquid — full drug profile →
Platinum-based doublet chemotherapy — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 80, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized, multicenter real-world study, which aims to investigate the efficacy and safety of Jinfukang oral liquid combined with chemotherapy as first-line treatment regimen for patients with driver-negative advanced NSCLC. 328 patients with unresectable stage IIIB-IV NSCLC and Qi-Yin deficiency will be divided into experimental (n=164) and control groups (n=164) according to the stratified blocked randomization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT05113888 — Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS) · Phase 2 · unknown
NCT05249244 — A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu · unknown
NCT04934059 — Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS). · Phase 4 · unknown
NCT02135835 — A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05098990 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Last refreshed: 29 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05098990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing